Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Long-term Consequences of Undiagnosed Celiac Seropositivity

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kårhus, LL, Skaaby, T, Petersen, J, Madsen, AL, Thuesen, BH, Schwarz, P, Rumessen, JJ & Linneberg, A 2020, 'Long-term Consequences of Undiagnosed Celiac Seropositivity', The American journal of gastroenterology, vol. 115, no. 10, pp. 1681-1688. https://doi.org/10.14309/ajg.0000000000000737

APA

Kårhus, L. L., Skaaby, T., Petersen, J., Madsen, A. L., Thuesen, B. H., Schwarz, P., Rumessen, J. J., & Linneberg, A. (2020). Long-term Consequences of Undiagnosed Celiac Seropositivity. The American journal of gastroenterology, 115(10), 1681-1688. https://doi.org/10.14309/ajg.0000000000000737

CBE

MLA

Vancouver

Author

Kårhus, Line Lund ; Skaaby, Tea ; Petersen, Janne ; Madsen, Anja Lykke ; Thuesen, Betina Heinsbæk ; Schwarz, Peter ; Rumessen, Jüri J ; Linneberg, Allan. / Long-term Consequences of Undiagnosed Celiac Seropositivity. In: The American journal of gastroenterology. 2020 ; Vol. 115, No. 10. pp. 1681-1688.

Bibtex

@article{c53d9a8df2ea4b7e856474ab92326ac8,
title = "Long-term Consequences of Undiagnosed Celiac Seropositivity",
abstract = "INTRODUCTION: Diagnosed celiac disease (CD) is associated with lymphoproliferative malignancy and gastrointestinal cancer, but little is known about the long-term consequences of undiagnosed CD. We aimed to investigate long-term consequences of undiagnosed CD for mortality and incidence of cancer and other chronic diseases.METHODS: We screened biobank serum samples for immunoglobulin (Ig) A and IgG tissue transglutaminase (TTG) and IgG deamidated gliadin peptide in a study of 8 population-based cohort studies comprising 16,776 participants examined during 1976-2012 and followed with >99% complete follow-up in Danish nationwide registries until December 31, 2017, regarding vital status and incidence of diseases. Undiagnosed CD was defined as antibody positivity (IgA-TTG or IgG-TTG ≥ 7 U/mL and/or IgG deamidated gliadin peptide ≥ 10 U/mL) in individuals without a diagnosis of CD recorded in the National Patient Register. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by Cox regression analyses with age as the underlying time scale.RESULTS: The prevalence of undiagnosed CD was 1.0% with no statistically significant increase over time. Undiagnosed CD was associated with increased risk of cancer overall (HR, 1.57; 95% CI, 1.16-2.11), gastrointestinal cancer (HR, 2.33; 95% CI, 1.35-4.04), cancer of the uterus (HR, 3.95; 95% CI, 1.46-10.69), breast cancer (HR, 1.98; 95% CI, 1.02-3.82), head and neck cancer (HR, 3.12; 95% CI, 1.15-8.43), and cardiovascular disease (HR, 1.37; 95% CI, 1.01-1.85). We found no statistically significant association between undiagnosed CD and mortality (HR, 1.19; 95% CI, 0.87-1.61).DISCUSSION: Undiagnosed CD was associated with increased risk of cardiovascular disease and cancer suggesting that untreated CD has serious long-term health consequences not only affecting the gastrointestinal tract (see Visual Abstract, Supplementary Digital Content, http://links.lww.com/AJG/B566).",
author = "K{\aa}rhus, {Line Lund} and Tea Skaaby and Janne Petersen and Madsen, {Anja Lykke} and Thuesen, {Betina Heinsb{\ae}k} and Peter Schwarz and Rumessen, {J{\"u}ri J} and Allan Linneberg",
year = "2020",
month = oct,
doi = "10.14309/ajg.0000000000000737",
language = "English",
volume = "115",
pages = "1681--1688",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "10",

}

RIS

TY - JOUR

T1 - Long-term Consequences of Undiagnosed Celiac Seropositivity

AU - Kårhus, Line Lund

AU - Skaaby, Tea

AU - Petersen, Janne

AU - Madsen, Anja Lykke

AU - Thuesen, Betina Heinsbæk

AU - Schwarz, Peter

AU - Rumessen, Jüri J

AU - Linneberg, Allan

PY - 2020/10

Y1 - 2020/10

N2 - INTRODUCTION: Diagnosed celiac disease (CD) is associated with lymphoproliferative malignancy and gastrointestinal cancer, but little is known about the long-term consequences of undiagnosed CD. We aimed to investigate long-term consequences of undiagnosed CD for mortality and incidence of cancer and other chronic diseases.METHODS: We screened biobank serum samples for immunoglobulin (Ig) A and IgG tissue transglutaminase (TTG) and IgG deamidated gliadin peptide in a study of 8 population-based cohort studies comprising 16,776 participants examined during 1976-2012 and followed with >99% complete follow-up in Danish nationwide registries until December 31, 2017, regarding vital status and incidence of diseases. Undiagnosed CD was defined as antibody positivity (IgA-TTG or IgG-TTG ≥ 7 U/mL and/or IgG deamidated gliadin peptide ≥ 10 U/mL) in individuals without a diagnosis of CD recorded in the National Patient Register. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by Cox regression analyses with age as the underlying time scale.RESULTS: The prevalence of undiagnosed CD was 1.0% with no statistically significant increase over time. Undiagnosed CD was associated with increased risk of cancer overall (HR, 1.57; 95% CI, 1.16-2.11), gastrointestinal cancer (HR, 2.33; 95% CI, 1.35-4.04), cancer of the uterus (HR, 3.95; 95% CI, 1.46-10.69), breast cancer (HR, 1.98; 95% CI, 1.02-3.82), head and neck cancer (HR, 3.12; 95% CI, 1.15-8.43), and cardiovascular disease (HR, 1.37; 95% CI, 1.01-1.85). We found no statistically significant association between undiagnosed CD and mortality (HR, 1.19; 95% CI, 0.87-1.61).DISCUSSION: Undiagnosed CD was associated with increased risk of cardiovascular disease and cancer suggesting that untreated CD has serious long-term health consequences not only affecting the gastrointestinal tract (see Visual Abstract, Supplementary Digital Content, http://links.lww.com/AJG/B566).

AB - INTRODUCTION: Diagnosed celiac disease (CD) is associated with lymphoproliferative malignancy and gastrointestinal cancer, but little is known about the long-term consequences of undiagnosed CD. We aimed to investigate long-term consequences of undiagnosed CD for mortality and incidence of cancer and other chronic diseases.METHODS: We screened biobank serum samples for immunoglobulin (Ig) A and IgG tissue transglutaminase (TTG) and IgG deamidated gliadin peptide in a study of 8 population-based cohort studies comprising 16,776 participants examined during 1976-2012 and followed with >99% complete follow-up in Danish nationwide registries until December 31, 2017, regarding vital status and incidence of diseases. Undiagnosed CD was defined as antibody positivity (IgA-TTG or IgG-TTG ≥ 7 U/mL and/or IgG deamidated gliadin peptide ≥ 10 U/mL) in individuals without a diagnosis of CD recorded in the National Patient Register. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated by Cox regression analyses with age as the underlying time scale.RESULTS: The prevalence of undiagnosed CD was 1.0% with no statistically significant increase over time. Undiagnosed CD was associated with increased risk of cancer overall (HR, 1.57; 95% CI, 1.16-2.11), gastrointestinal cancer (HR, 2.33; 95% CI, 1.35-4.04), cancer of the uterus (HR, 3.95; 95% CI, 1.46-10.69), breast cancer (HR, 1.98; 95% CI, 1.02-3.82), head and neck cancer (HR, 3.12; 95% CI, 1.15-8.43), and cardiovascular disease (HR, 1.37; 95% CI, 1.01-1.85). We found no statistically significant association between undiagnosed CD and mortality (HR, 1.19; 95% CI, 0.87-1.61).DISCUSSION: Undiagnosed CD was associated with increased risk of cardiovascular disease and cancer suggesting that untreated CD has serious long-term health consequences not only affecting the gastrointestinal tract (see Visual Abstract, Supplementary Digital Content, http://links.lww.com/AJG/B566).

U2 - 10.14309/ajg.0000000000000737

DO - 10.14309/ajg.0000000000000737

M3 - Journal article

C2 - 32558687

VL - 115

SP - 1681

EP - 1688

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 10

ER -

ID: 60188527